Rivals In India Begin Shadow Fight As Researchers Find Possible Link Between Sanofi-Aventis' Lantus And Cancer
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - As Sanofi-Aventis engages in fire fighting to counter claims made by the European Association for the Study of Diabetes that there is a link between Sanofi's Lantus (insulin glargine) and an increased risk of cancer, top diabetologists interviewed by PharmAsia News in India said they would take a more cautious approach on use of the drug until more research data is published
You may also be interested in...
India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).